“I suddenly noticed blurry vision in one eye, and it got much worse over the course of a couple days. My doctor diagnosed me with a retinal vein occlusion and said I can lose my vision permanently without frequent treatment.”
WHAT IS RETINAL VEIN OCCLUSION (RVO)?
The retina needs a constant supply of oxygen and nutrients delivered by blood vessels. In retinal vein occlusion (RVO), a blockage occurs in either the central retinal vein (CRVO) or a branch retinal vein (BRVO). As a result of the RVO, ischemia develops within the retina and VEGF levels are elevated. Patients with RVO are at risk for developing:
- Macular edema: Fluid leakage into the center of the retina causing decreased vision.
- Retinal and Anterior Segment Neovascularization: Abnormal, blood vessels grow in response to ischemia and excess VEGF. Neovascularization easily bleeds and may lead to severe vision loss and neovascular glaucoma.
TARCOCIMAB TEDROMER (KSI-301) FOR RVO
Our therapeutic candidate tarcocimab tedromer, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, tarcocimab tedromer may relieve the high treatment burden for patients, their family members, and physicians.
Tarcocimab tedromer is being developed towards a once every two months or longer treatment regimen.